Report cover image

Global Meningitis Diagnostic Testing Market - 2024-2031

Publisher DataM Intelligence 4Market Research LLP
Published Jul 10, 2024
Length 186 Pages
SKU # DTAM18976653

Description

Global Meningitis Diagnostic Testing Market - 2024-2031


Global Meningitis Diagnostic Testing Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Meningitis is an infection and inflammation of the meninges, the fluid and membranes surrounding the brain and spinal cord. Symptoms include headache, fever, and stiff neck. Most cases in the US are caused by viral infections, but bacteria, parasites, and fungi can also cause it. Some cases improve without treatment, while others can cause death and require emergency antibiotic treatment. Seeking immediate medical care is crucial for preventing serious complications.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of meningitis

The global meningitis diagnostic testing market is driven by rising global prevalence, demand for advanced diagnostics, point-of-care diagnostic services, and research and development investments for effective diagnosis and treatment, with the forecast period expected to be dominated by these factors.

For instance, according to a recent article published in NCBI, The incidence of meningitis worldwide is estimated to be 20 cases per 100,000 people; that is, about 1.2 million; the incidence and causes vary across geographic regions.

Shortage of skilled professionals

Accurate diagnosis of meningitis is crucial for timely and effective treatment, as the condition can progress rapidly and result in severe complications or death. However, several challenges related to the shortage of skilled healthcare professionals, particularly in rural and underdeveloped areas, can restrict the usage and effectiveness of diagnostic tests.

The lack of skilled professionals can lead to delays in diagnosis, which is critical for conditions like meningitis that progress rapidly. Delayed diagnosis can result in worse outcomes, including higher morbidity and mortality rates.

Segment Analysis

The global meningitis diagnostic testing market is segmented based on infection type, diagnosis type, end-user, and region.

The PCR assay from the diagnosis type segment accounted for approximately 39.5% of the meningitis diagnostic testing market share

The PCR assay from the diagnosis type segment accounted for approximately 39.5%. The PCR assay segment is expected to dominate during the forecast period owing to the factors like, the availability of RT-PCR platforms, which provide results in less than two hours, including multi-target and single-target detection tests. Technological advancements in PCR assays, which reduce turnaround times and promote precise diagnosis, are expected to further drive the segment's growth. The high sensitivity and precision of PCR tests are expected to further increase their adoption in meningitis testing.

For instance, in January 2024, QIAGEN announced that its QIAstat-Dx Meningitis/Encephalitis Panel, a qualitative multiplexed nucleic acid-based in vitro diagnostic test has received approval from the Health Sciences Authority Singapore (HSA). The QIAstat-Dx system is designed for use in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens.3

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors due to strategic initiatives and the presence of leading players. High adoption of advanced diagnostic devices, easy access to test kits, increased awareness about early diagnosis, and an increase in diagnostic centres are expected to fuel region expansion. Government initiatives to promote infectious disease diagnosis offer lucrative growth opportunities in the future.

Covid 19 Impact Analysis

The COVID-19 pandemic significantly impacted the meningitis diagnostics testing market, as many people struggled to get routine immunizations due to the unavailability of primary care or self-isolation requirements. For instance, in February 2022, a study in Clinical Epidemiology and Global Health reported a meningitis outbreak in the Democratic Republic of Congo, causing strain on healthcare systems and a high case fatality rate of 50%.

Market Segmentation

By Infection Type
• Bacterial
• Viral
• Fungal
• Others

By Diagnosis Type
• Latex Agglutination Tests
• PCR Assay
• Lateral Flow Assay
• ELISA Tests
• Culture Test
• Others

By End-User
• Hospitals
• Diagnostic Laboratories
• Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc, Seegene Inc., BioFire Diagnostics LLC (BioMérieux), Teco Diagnostics, ELITech Group, Transasia Bio-Medicals Ltd, Lepu Medical Technology Eurolyser Diagnostica, Gold Standard Diagnosticsa, Biorad laboratories Inc among others.

Key Developments

On October 26, 2023, LumiraDx unveiled a groundbreaking development in the field of medical diagnostics—the launch of its cutting-edge meningitis NxGen MenB & Group C/G/Y Assay. This innovative molecular test represents a significant leap forward in point-of-care testing for meningitis B and other serogroups, promising a revolution in the timely diagnosis and treatment of this critical health condition.

In July 2022, Abacus Diagnostica, a Uniogen company, launched a new rapid PCR test GenomEra assay kit (HSV-1/2, VZV + EV Assay Kit) in the European markets for the fast identification of viruses causing viral meningitis and encephalitis. This is a significant development in medical technology as it will allow for faster and more accurate diagnoses of these serious illnesses.

Why Purchase the Report?
• To visualize the global meningitis diagnostic testing market segmentation based on infection type, diagnosis type, end user, and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the meningitis diagnostic testing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global meningitis diagnostic testing market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

186 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Infection Type
3.2. Snippet by Diagnosis Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of meningitis
4.1.1.2. Rise of technological advancement in testing kits
4.1.2. Restraints
4.1.2.1. Shortage of skilled professionals
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Infection Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
7.1.2. Market Attractiveness Index, By Infection Type
7.2. Bacterial *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Viral
7.4. Fungal
7.5. Others
8. By Diagnosis Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
8.1.2. Market Attractiveness Index, By Diagnosis Type
8.2. Latex Agglutination Tests*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. PCR Assay
8.4. Lateral Flow Assay
8.5. ELISA Tests
8.6. Culture Test
8.7. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Laboratories
9.4. Clinics
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Thermo Fisher Scientific, Inc*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Seegene Inc
12.3. BioFire Diagnostics LLC (BioMérieux)
12.4. Teco Diagnostics
12.5. ELITech Group
12.6. Transasia Bio-Medicals Ltd
12.7. Lepu Medical Technology
12.8. Eurolyser Diagnostica
12.9. Gold Standard Diagnostics
12.10. Bio-Rad Laboratories, Inc.
IST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us